MISC

2009年9月

Presentation and management of intravascular large B-cell lymphoma

The Lancet Oncology
  • Kazuyuki Shimada
  • ,
  • Tomohiro Kinoshita
  • ,
  • Tomoki Naoe
  • ,
  • Shigeo Nakamura

10
9
開始ページ
895
終了ページ
902
記述言語
英語
掲載種別
書評論文,書評,文献紹介等
DOI
10.1016/S1470-2045(09)70140-8

Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity of non-Hodgkin lymphoma according to the current WHO classification. This rare form of B-cell lymphoma is characterised by selective growth of tumour cells in the lumina of small vessels of various organs. Strange characteristics of IVLBCL, including the absence of marked lymphoadenopathy and the usually aggressive clinical behaviour, result in the delay of timely and accurate diagnosis and fatal complications. Thus, the prognosis of IVLBCL is extremely poor. The success achieved with the anti-CD20 chimeric monoclonal antibody, rituximab, represents an important milestone in the clinical practice of B-cell lymphoma. An advantage of adding rituximab to conventional chemotherapies has been shown, in the process of increasing our understanding of the clinical and pathological manifestations for IVLBCL. This Review describes the cutting edge of research on IVLBCL, and discusses the unsolved issues from biological and clinical perspectives to provide a better understanding of this rare lymphoma. © 2009 Elsevier Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/S1470-2045(09)70140-8
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/19717091
ID情報
  • DOI : 10.1016/S1470-2045(09)70140-8
  • ISSN : 1470-2045
  • PubMed ID : 19717091
  • SCOPUS ID : 69149087791

エクスポート
BibTeX RIS